FIBRINOGEN PLASMA-LEVELS AS A MARKER OF THROMBIN ACTIVATION IN DIABETES

被引:54
作者
CERIELLO, A [1 ]
TABOGA, C [1 ]
GIACOMELLO, R [1 ]
FALLETI, E [1 ]
DESTASIO, G [1 ]
MOTZ, E [1 ]
LIZZIO, S [1 ]
GONANO, F [1 ]
BARTOLI, E [1 ]
机构
[1] GEN HOSP,DIABETOL UNIT,UDINE,ITALY
关键词
D O I
10.2337/diabetes.43.3.430
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study attempted to verify the existence of a correlation between fibrinogen, a major cardiovascular risk factor in diabetes, and indexes of thrombin generation and action, prothrombin fragment 1 + 2 (F1 + 2), and D-dimer (D-D), in a group of diabetic subjects compared with a matched control group. Forty insulin-dependent diabetes mellitus patients and 30 matched healthy control subjects participated in this study. The subjects were tested for the following parameters: fibrinogen, prothrombin F1 + 2, D-D, fasting glycemia, and HbA(1c). In addition, 5 diabetic subjects who maintained stable fibrinogen plasma levels >300 mg/dl for at least 6 months before the study were treated with 12,500 U/day subcutaneous heparin for 7 days. Diabetic subjects showed increased levels of fibrinogen, prothrombin F1 + 2, and D-D plasma levels. Simple linear regression analysis detected a positive correlation between fibrinogen and prothrombin F1 + 2, D-D, and glycosylated HbA(1c). In the five diabetic subjects treated with heparin fibrinogen, prothrombin F1 + 2 and D-D levels decreased at the end of the treatment. All these parameters returned to baseline after 7 days of washout. These data indicate that fibrinogen plasma levels are correlated to parameters of thrombin activation in plasma in diabetic patients and suggest that high fibrinogen plasma levels might be a risk marker for cardiovascular disease in diabetes because it is an expression of an existing thrombophilia.
引用
收藏
页码:430 / 432
页数:3
相关论文
共 20 条
[1]   GENERATION OF COMBINED PROTHROMBIN ACTIVATION PEPTIDE (F1.2) DURING CLOTTING OF BLOOD AND PLASMA [J].
ARONSON, DL ;
STEVAN, L ;
BALL, AP ;
FRANZA, BR ;
FINLAYSON, JS .
JOURNAL OF CLINICAL INVESTIGATION, 1977, 60 (06) :1410-1418
[2]  
CERIELLO A, 1992, HAEMOSTASIS, V22, P50
[3]  
CERIELLO A, 1993, DIABETES NUTR METAB, V6, P203
[4]   EFFECT OF FIBRINOGENOLYTIC PRODUCT-D AND PRODUCT-E ON FIBRINOGEN AND ALBUMIN SYNTHESIS IN THE RAT [J].
FRANKS, JJ ;
KIRSCH, RE ;
FRITH, LO ;
PURVES, LR ;
FRANKS, WT ;
FRANKS, JA ;
MASON, P ;
SAUNDERS, SJ .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 67 (02) :575-580
[5]   HYPERFIBRINOGENEMIA - AN IMPORTANT RISK FACTOR FOR VASCULAR COMPLICATIONS IN DIABETES [J].
GANDA, OP ;
ARKIN, CF .
DIABETES CARE, 1992, 15 (10) :1245-1250
[6]  
GENSINI G F, 1990, Fibrinolysis, V4, P78
[7]   DETECTION AND RELEVANCE OF CROSSLINKED FIBRIN DERIVATIVES IN BLOOD [J].
GRAEFF, H ;
HAFTER, R .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1982, 8 (01) :57-68
[9]   FIBRINOGEN AND RISK OF CARDIOVASCULAR-DISEASE - THE FRAMINGHAM-STUDY [J].
KANNEL, WB ;
WOLF, PA ;
CASTELLI, WP ;
DAGOSTINO, RB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 258 (09) :1183-1186
[10]   FIBRIN AND FIBRINOGEN-RELATED ANTIGENS IN PATIENTS WITH STABLE AND UNSTABLE CORONARY-ARTERY DISEASE [J].
KRUSKAL, JB ;
COMMERFORD, PJ ;
FRANKS, JJ ;
KIRSCH, RE .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (22) :1361-1365